A. SARS-CoV-2 omicron variant spike pseudovirus expressing luciferase is treated with SARS-CoV-2 neutralizing monoclonal antibody, clone G10xA1 (Cat # MAB23153), and then added into 293T-ACE cells. B. SARS-CoV-2 omicron variant spike pseudovirus expressing luciferase is treated with SARS-CoV-2 neutralizing monoclonal antibody, clone 7A7, and then added into 293T-ACE cells. C. SARS-CoV-2 omicron variant spike pseudovirus expressing luciferase is treated with SARS-CoV-2 neutralizing monoclonal antibody, clone 5D6, and then added into 293T-ACE cells. D. SARS-CoV-2 omicron variant spike pseudovirus expressing luciferase is treated with SARS-CoV-2 neutralizing monoclonal antibody, clone 8C4, and then added into 293T-ACE cells.